Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Currency in USD	2025
Operating Income	3.60 Billion
Income Before Tax	3.36 Billion
Income Tax Expense	687.00 Million
Net Income	2.67 Billion
Eps	6.03
Epsdiluted	6.02
Weighted Average Shs Out	443.44 Million
Weighted Average Shs Out Dil	443.83 Million
Research And Development Expenses	N/A
Selling General And Administrative Expenses	2.38 Billion
Depreciation And Amortization	487.00 Million
Interest Expense	222.00 Million
Interest Income	93.00 Million
Net Interest Income	-129 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	6.80 Billion
Ebitda	4.08 Billion
Source	edgar
Ebit	3.58 Billion

Zoetis Inc. Annual Reports (10-K)